What is the monthly injection for MS?

The monthly injection for MS is Kesimpta, the brand name for ofatumumab. It is a prescription medicine for adults with relapsing forms of Multiple sclerosis. After three weekly starter doses and one week without a dose, most people take one injection each month. A prefilled pen delivers it under the skin.

Kesimpta changes the way the immune system works. It lowers a group of immune cells called B cells, which can play a part in attacks on the brain and spinal cord. The goal is to cut relapses and reduce new areas of damage seen on MRI scans. It cannot cure MS or fix every symptom that is already there.

Why is Kesimpta given once a month?

Ofatumumab is a monoclonal antibody. It finds a protein called CD20 on certain B cells and helps the body clear those cells. B cells usually help fight infection. But in MS, some also support immune attacks that harm myelin, the coating around nerves.

The dose schedule keeps the targeted B-cell level low between treatments. Treatment begins with injections in weeks zero, one and two. There is no injection in week three. The first monthly dose comes in week four, followed by one dose each month.

This starter schedule matters. A person should follow the dates given by the prescribing team, not pick a handy monthly date from the start. The clinician or MS nurse can also explain what to do if a dose is late or missed.

Here’s a detail people often miss: monthly dosing does not mean the medicine leaves the body after 30 days. Its effect on B cells carries on between doses. Stopping treatment may also affect immune activity after the final injection date, so any break should be planned with the MS team.

How do you take the injection at home?

Kesimpta uses Subcutaneous administration, which means the medicine goes into the fatty layer under the skin. It does not enter a vein or go deep into a muscle. The usual dose comes in a single-use, prefilled Sensoready pen.

A clinician should teach the person or their caregiver how to use the pen before the first home dose. Common injection sites are the front of the thigh or the lower abdomen. A caregiver may also use the outer upper arm. Avoid skin that is sore, bruised, infected, scarred or marked by stretch marks.

The pen is usually kept in its original carton in a refrigerator. It must not be frozen or shaken. Before each dose, check the label, expiry date and viewing window. Local storage directions and the consumer medicine information explain how long it can stay outside the refrigerator.

A useful injection routine is simple:

1. Choose the scheduled day and set a repeating reminder.
2. Remove the pen from the refrigerator as directed and let it reach room temperature without heating it.
3. Wash and dry your hands, then check the pen and medicine.
4. Clean the selected skin site and let it dry.
5. Use the pen exactly as demonstrated by the MS nurse.
6. Place the used pen in an approved sharps container.
7. Record the dose and any reaction.

Changing the injection site each time can reduce skin irritation. A written dose record also helps when travel, illness or appointments disrupt the usual routine.

Who may be offered this treatment?

Kesimpta is used for relapsing forms of MS in adults. This group may include relapsing-remitting MS and active secondary progressive MS, based on local approval and the clinician's review.

A neurologist may consider it when MRI scans or relapses show active disease. It may also suit someone who wants an effective treatment they can take at home. The choice still depends on disease activity, past medicines, infection risk, pregnancy plans, other health problems and personal preference.

The monthly plan may feel easier than frequent injections, daily tablets or visits to an infusion centre. Still, ease is only one part of the choice. A treatment must suit the person's MS pattern and medical risks.

In real life, the word “monthly” sounds simple until the first dose calendar arrives. Those weekly loading doses can catch people by surprise. Many patients find it easier once they add all four starting weeks and the later monthly dates to their phone before taking the first dose.

What checks are needed before the first dose?

The prescribing team checks infections, vaccines, current medicines and immune health before treatment. Blood tests may include hepatitis B screening and checks of immune function. Someone with an active infection may need to wait until it clears.

Hepatitis B needs extra care because B-cell treatments can cause a past infection to become active again. A positive screening result does not always rule out treatment. But it does call for advice from clinicians with the right skills and may mean closer checks.

Vaccines should be reviewed before therapy begins. Live vaccines are usually avoided during treatment and until the immune system has recovered after stopping. Other vaccines may not work as well while B cells are suppressed. The MS team can plan the timing without leaving the person unprotected longer than needed.

Pregnancy plans should be discussed before the first dose. People who could become pregnant need clear advice about birth control during treatment and for the required time after their last dose. Breastfeeding also calls for a personal discussion with the treating clinician.

What might you notice after a dose?

The first injection is most likely to cause a general reaction. Symptoms may include fever, headache, muscle aches, chills or tiredness. Reactions around the injection site can include redness, pain, swelling or itching. Many are mild or moderate, but the care team should explain which signs need urgent help.

Breathing trouble, swelling of the face or throat, severe dizziness, widespread hives or a reaction that gets worse fast requires urgent medical care. A person should not take another dose until a clinician has checked a suspected serious allergic reaction.

Because ofatumumab lowers B cells, it can raise infection risk. Report a new fever, lasting cough, painful urination, shingles-like blisters or an infection that will not clear. The treating team may delay a dose while an infection is active.

Changes in vision, strength, speech, thinking or coordination also need quick medical review. These symptoms can have several causes, including an MS relapse. A rare but serious brain infection is another reason clinicians treat new neurological symptoms with care.

One detail often overlooked is the difference between an injection reaction and an MS relapse. Flu-like symptoms that begin soon after a dose may be a treatment reaction. New neurological symptoms lasting more than 24 hours may suggest disease activity, mainly when there is no fever or infection. The person should contact the MS service instead of deciding alone.

How is this different from a four-week infusion?

People sometimes use “monthly injection” for any medicine given by needle every four weeks. That can blur the difference between ofatumumab and Natalizumab.

Natalizumab, sold as Tysabri, is often given by intravenous infusion about every four weeks. It works by reducing the movement of immune cells into the brain and spinal cord. It is usually given at a clinic or infusion service. Kesimpta is injected under the skin at home after training and targets CD20-positive B cells.

These treatments have different checks and risks. Natalizumab needs special care around the JC virus because of its link to progressive multifocal leukoencephalopathy, known as PML. Ofatumumab calls for attention to B-cell depletion, infections, hepatitis B and immune response.

Neither medicine should be chosen by needle frequency alone. A neurologist weighs disease control, MRI findings, blood results, past treatments and the risks that matter to that person.

How will you know whether it is working?

Most people cannot feel the treatment controlling MS each day. Success is measured over time through relapses, neurological exams and MRI scans. The goal is fewer attacks, fewer new or growing lesions and slower disability progression.

Follow-up may include blood tests to check immune measures, liver health or infection risk, based on the person's treatment plan. The clinician will also ask about missed doses, side effects and symptom changes.

One quiet month does not prove the medicine works. And one hard symptom day does not prove it has failed. Heat, poor sleep, stress or infection can make old MS symptoms feel worse without causing new nerve damage. A new relapse or fresh MRI activity needs a proper review because it may change the treatment plan.

Another point people miss is that effective treatment and symptom care do different jobs. Kesimpta aims to reduce new immune damage. It may not clear fatigue, pain, stiffness, bladder problems or balance issues that already exist. Rehabilitation, exercise advice and symptom medicines may still help.

What should you ask before choosing it?

A good treatment talk should cover more than the dose schedule. Ask the neurologist:

• Why does this medicine fit my type and level of MS activity?
• Which tests do I need before starting?
• Which vaccines should I receive first?
• Who will teach me to use and store the pen?
• What should I do if I miss a dose or become unwell?
• Which symptoms require urgent medical care?
• How often will I have blood tests, MRI scans and reviews?
• How would pregnancy, travel or surgery affect my plan?

Cost and access matter too. Coverage rules differ by country and health system. The clinic or pharmacist can confirm approval steps, supply plans and what to do if a pen is damaged or lost.

How can you make monthly treatment safer and easier?

Keep the medicine plan in one place. Write down dose dates, injection sites, test results and clinic contact details. Set reminders several days before each dose, leaving time to arrange a refill.

Plan ahead before travelling. Ask the pharmacist how to carry the pen at the right temperature and which papers you need for airport security. Never put it in checked luggage, where temperature and handling cannot be controlled.

Tell every treating clinician that you use a B-cell treatment. This matters before vaccines, surgery and infection treatment. Do not stop or delay Kesimpta over a minor concern without contacting the MS team, unless you need emergency care.

Action takeaway: If you were told about a monthly MS injection, confirm whether the name is Kesimpta or ofatumumab, then ask your neurologist for the exact starter schedule, safety checks and missed-dose plan before the first injection.

Common questions

What is the 6 monthly injection for multiple sclerosis?

Ocrevus (ocrelizumab) is an MS medicine given every six months after the first two doses. It is given through a vein at a clinic, so it is an infusion rather than a regular injection.

What are the common side effects of MS injections?

Common side effects include redness, pain, swelling, or itching where the shot is given. Some people also have headaches, tiredness, fever, chills, or other flu-like feelings.

What injections are given for multiple sclerosis?

MS injections include interferon beta, glatiramer acetate, and Kesimpta (ofatumumab). They are given on different schedules, from several times a week to once a month.

What is the most successful treatment for multiple sclerosis (MS)?

There is no single MS treatment that works best for everyone. Strong medicines such as Ocrevus, Kesimpta, Tysabri, and Lemtrada can reduce attacks, but a specialist must choose the safest option for each person.